The U.S. Supreme Court on Monday asked the Obama administration to weigh in on an antitrust question that could affect the ability of drug companies to settle patent disputes and increase their antitrust liability.
The justices called for the views of the solicitor general on whether to grant review in SmithKline Beecham v. King Drug Co. of Florence, challenging a decision by the U.S. Court of Appeals for the Third Circuit.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
